Thoracic Surgery Department, Ain Shams University Hospital, Cairo, Egypt.
Cardio-Thoracic Surgery Department, Ain Shams University Hospital, Cairo, Egypt.
Interact Cardiovasc Thorac Surg. 2021 May 10;32(5):761-763. doi: 10.1093/icvts/ivaa338.
A best evidence topic was written according to a structured protocol. The question addressed was: In patients with mesothelioma who develop a local recurrence after macroscopic complete resection (MCR) surgery, does performing a second radical surgery lead to improvement in survival? A total of 2076 papers were identified using the reported search, of which 3 represented the best evidence to answer the clinical question. The authors, date, journal, country, study type, population, outcomes and key results are tabulated. The 2 largest studies included 16 patients each who underwent a second surgery for radical resection of recurrence after MCR for mesothelioma. One study (with 16 chest wall resections) had no in-hospital mortality, whereas the other study showed 2/16 (12.5%) patients dying in the hospital, both of whom had a contralateral pleurectomy. One study correlated the median survival after the second surgery with the time to recurrence and epithelioid pathology. The other study showed better post-recurrence survival after a second surgery, with patients having a significantly longer median post-recurrence survival (16 months) compared with those who received other types of second-line therapy (9 months) and those who received no therapy at all (2 months) (P < 0.0005), although selection bias is a possibility. The last study included 8 patients who underwent a second surgery for radical intent after MCR for mesothelioma. The median time to recurrence was 29 months and the survival after second surgery was 14.5 months with no correlation to disease-free interval (expected due to the small number of patients). In patients presenting with recurrence of mesothelioma after an MCR procedure, radical surgery to resect the recurrent tumour could have a role in improvement of survival in selected patients. Positive prognostic factors include epithelioid pathology and a longer disease-free interval after the first procedure.
一个最佳证据主题是根据结构化方案撰写的。提出的问题是:在接受大体完全切除 (MCR) 手术后局部复发的间皮瘤患者中,进行第二次根治性手术是否会改善生存?使用报告的搜索共确定了 2076 篇论文,其中 3 篇代表了回答临床问题的最佳证据。作者、日期、期刊、国家、研究类型、人群、结局和关键结果均列于表中。最大的两项研究均纳入了 16 例患者,他们因 MCR 后复发而行第二次根治性切除术。其中一项研究(16 例行胸腔壁切除术)无院内死亡,而另一项研究显示 16 例中有 2 例(12.5%)患者在院内死亡,这两例均行对侧胸膜切除术。一项研究将第二次手术后的中位生存与复发时间和上皮样病理相关联。另一项研究显示第二次手术后的复发后生存更好,与接受二线其他治疗的患者(9 个月)和未接受任何治疗的患者(2 个月)相比,接受第二次手术的患者具有显著更长的中位复发后生存时间(16 个月)(P<0.0005),尽管存在选择偏倚的可能性。最后一项研究纳入了 8 例因 MCR 后复发而行根治性手术的患者。中位复发时间为 29 个月,第二次手术后的生存时间为 14.5 个月,与无疾病间期无关(由于患者数量较少,故预期如此)。在接受 MCR 手术后复发的间皮瘤患者中,对复发性肿瘤进行根治性手术切除可能会改善某些患者的生存。阳性预后因素包括上皮样病理和第一次手术后无疾病间期较长。